EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

Summary

The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction \[NSTEMI\] and ST-segment elevation myocardial infarction \[STEMI\]).

Timeline

Start

2022-10-26

Primary completion

2027-05-29

Completion

2027-05-29

Drugs

Indications